Share on StockTwits

Hospira (NYSE:HSP) CFO Thomas E. Werner unloaded 10,000 shares of the company’s stock on the open market in a transaction dated Friday, August 15th. The stock was sold at an average price of $55.13, for a total value of $551,300.00. Following the completion of the sale, the chief financial officer now directly owns 54,614 shares in the company, valued at approximately $3,010,870. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Hospira (NYSE:HSP) traded up 2.24% on Wednesday, hitting $55.13. 834,729 shares of the company’s stock traded hands. Hospira has a one year low of $38.11 and a one year high of $56.78. The stock has a 50-day moving average of $52. and a 200-day moving average of $47.50. The company has a market cap of $9.302 billion and a price-to-earnings ratio of 52.00.

Hospira (NYSE:HSP) last released its earnings data on Wednesday, July 30th. The company reported $0.72 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.56 by $0.16. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter last year, the company posted $0.55 earnings per share. Hospira’s revenue was up 10.7% compared to the same quarter last year. On average, analysts predict that Hospira will post $2.41 earnings per share for the current fiscal year.

A number of research firms have recently commented on HSP. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Hospira in a research note on Thursday, July 31st. They now have a $55.00 price target on the stock, up previously from $42.00. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Hospira in a research note on Thursday, July 31st. They now have a $67.00 price target on the stock. Finally, analysts at Barclays reiterated an “equal weight” rating on shares of Hospira in a research note on Thursday, July 31st. They now have a $47.00 price target on the stock, up previously from $43.00. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $51.38.

Hospira, Inc (NYSE:HSP) is a provider of injectable drugs and infusion technologies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.